Correction to: Nature Communications https://doi.org/10.1038/s41467-023-36566-1, published online 07 March 2023
The original version of this Article contained errors in the Supplementary Information. The section titled “Supplementary Text: Determination of symptom status at the time of SARS-CoV-2 testing” listed some symptoms that were not included in the analysis. The list has been corrected in the updated Supplementary Information pdf.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Grewal, R., Nguyen, L., Buchan, S.A. et al. Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. Nat Commun 15, 10709 (2024). https://doi.org/10.1038/s41467-024-55350-3
Published:
Version of record:
DOI: https://doi.org/10.1038/s41467-024-55350-3
